First New York Securities’s Amicus Therapeutics FOLD Stock Holding History

First New York Securities’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-500	Closed	-$3.7K	–	121
2016 Q3	$3.7K	Buy	+500	New	+$3.38K	﹤0.01%	219
2016 Q2	–	Sell	-500	Closed	-$4.22K	–	242
2016 Q1	$4.22K	Buy	+500	New	+$3.54K	﹤0.01%	206

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

First New York Securities's FOLD Position: Q4 2016 in Review

First New York Securities sold out of Amicus Therapeutics (FOLD) in Q4 2016, closing a stake of 500 shares — an estimated $3.7K sold.

First New York Securities first reported a position in FOLD in Q1 2016 and held it in 2 quarters. The position peaked at $4.22K in Q1 2016. 135 funds tracked by Wall St. Rank hold FOLD as of Q4 2016.

First New York Securities reported no remaining Amicus Therapeutics position as of Q4 2016 after selling out during the quarter.
First New York Securities sold 500 Amicus Therapeutics shares in Q4 2016, an estimated $3.7K.
First New York Securities first reported a position in Amicus Therapeutics in Q1 2016 and held it in 2 quarters.
First New York Securities's Amicus Therapeutics position peaked at $4.22K in Q1 2016.
135 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2016.

Based on First New York Securities's 13F filing for Q4 2016, filed 7 Feb 2017.